Ahren Innovation Capital is anchored by nine Science Partners whose inventions and companies are collectively valued at over $100B, including Nobel laureates and creators of technologies like Illumina's genome sequencing chemistry and the cancer drug Lynparza, with founding partners including the President of the Royal Society and Masters of Trinity College making it essentially a commercial extension of top UK science institutions. The fund focuses exclusively on four science-driven domains—Brain & AI, Genetics & Platform Technologies, Space & Robotics, and Planet & Efficient Energy—and operates as patient capital willing to support companies from pre-seed through pre-IPO in frontier areas with very long development cycles.